[FG] Marzolini Catia

Berton, Mattia et al. (2024) ‘Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure’, Open Forum Infectious Diseases, 11(10), p. 11. Available at: https://doi.org/10.1093/ofid/ofae585.

Thoueille, Paul et al. (2024) ‘Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV’, Clinical Pharmacology & Therapeutics, 115(6), pp. 1450–1459. Available at: https://doi.org/10.1002/cpt.3240.

Bongiovanni, Marco et al. (2024) ‘Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations’, European Journal of Clinical Microbiology & Infectious Diseases [Preprint]. Available at: https://doi.org/10.1007/s10096-024-04844-5.

Pham, Thao et al. (2024) ‘DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy’, npj Systems Biology and Applications, 10(1). Available at: https://doi.org/10.1038/s41540-024-00374-0.

Bettonte, Sara et al. (2024) ‘Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs’, CPT: Pharmacometrics & Systems Pharmacology, 13(5), pp. 781–794. Available at: https://doi.org/10.1002/psp4.13118.

Briki, M. et al. (2024) ‘Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update’, Journal of Chromatography B, 1236, p. 124039. Available at: https://doi.org/10.1016/j.jchromb.2024.124039.

Bettonte, Sara et al. (2024) ‘Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study’, Open Forum Infectious Diseases, 11(4). Available at: https://doi.org/10.1093/ofid/ofae171.

Bettonte, Sara et al. (2024) ‘Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study’, Clinical Infectious Diseases [Preprint]. Available at: https://doi.org/10.1093/cid/ciae060.

Abela, Irene A et al. (2024) ‘Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk’, Open Forum Infectious Diseases, 11. Available at: https://doi.org/10.1093/ofid/ofae502.

Ambrosioni, Juan et al. (2024) ‘Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study’, Infectious Diseases and Therapy, null. Available at: https://doi.org/10.1007/s40121-024-00935-0.

Berton, Mattia et al. (2024) ‘Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data’, Clinical Infectious Diseases, 78, pp. 98–110. Available at: https://doi.org/10.1093/cid/ciad495.

Haefliger, David et al. (2024) ‘Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report’, Seminars in Dialysis [Preprint]. Available at: https://doi.org/10.1111/sdi.13224.

Marzolini, Catia et al. (2024) ‘Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir’, Expert Opinion on Drug Metabolism and Toxicology [Preprint]. Available at: https://doi.org/10.1080/17425255.2024.2415295.

Thoueille, Paul et al. (2024) ‘Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures’, Open Forum Infectious Diseases, 11. Available at: https://doi.org/10.1093/ofid/ofae023.

Thoueille, Paul et al. (2024) ‘Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland’, The Lancet Regional Health - Europe, 36. Available at: https://doi.org/10.1016/j.lanepe.2023.100793.

Cortés, K.C. et al. (2023) ‘T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C’, Open Forum Infectious Diseases, 10(11). Available at: https://doi.org/10.1093/ofid/ofad514.

Sebastiani G et al. (2023) ‘Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?’, Hepatology (Baltimore, Md.), 78(5), pp. E87–E88. Available at: https://doi.org/10.1097/hep.0000000000000465.

Marzolini C et al. (2023) ‘Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen.’, British journal of clinical pharmacology, 89(9), pp. 2739–2746. Available at: https://doi.org/10.1111/bcp.15754.

Bettonte S et al. (2023) ‘Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.’, British journal of clinical pharmacology [Preprint]. Available at: https://doi.org/10.1111/bcp.15867.

Berton M et al. (2023) ‘Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.’, Open forum infectious diseases, 10(7), p. ofad361. Available at: https://doi.org/10.1093/ofid/ofad361.

Bettonte S et al. (2023) ‘Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.’, European journal of drug metabolism and pharmacokinetics, 48(4), pp. 353–362. Available at: https://doi.org/10.1007/s13318-023-00833-9.

Haefliger D et al. (2023) ‘Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.’, 89(7). Available at: https://doi.org/10.1111/bcp.15743.

Avery, Emma F et al. (2023) ‘Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study’, Clinical Infectious Diseases, 76(11), pp. 1969–1979. Available at: https://doi.org/10.1093/cid/ciad033.

Erba A et al. (2023) ‘Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient.’, Virology journal, 20(1), p. 89. Available at: https://doi.org/10.1186/s12985-023-02058-3.

Schoepf, Isabella C et al. (2023) ‘Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years’, The Lancet Healthy Longevity, 4(5), pp. e211–e218. Available at: https://doi.org/10.1016/s2666-7568(23)00037-5.

Surial, B. et al. (2023) ‘External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection’, Journal of Hepatology, 78(5), pp. 947–957. Available at: https://doi.org/10.1016/j.jhep.2022.12.029.

Bettonte S et al. (2023) ‘Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(7), pp. 1225–1236. Available at: https://doi.org/10.1093/cid/ciac901.

Marzolini C and Khoo S (2023) ‘Response to ‘A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir’.’, 113(4). Available at: https://doi.org/10.1002/cpt.2809.

Berton M et al. (2023) ‘Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.’, Clinical pharmacokinetics, 62(2), pp. 277–295. Available at: https://doi.org/10.1007/s40262-022-01194-3.

Hodge, Daryl et al. (2023) ‘Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature’, JAIDS Journal of Acquired Immune Deficiency Syndromes, 92(2), pp. 97–105. Available at: https://doi.org/10.1097/qai.0000000000003122.

Ambrosioni, Juan et al. (2023) ‘Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023’, HIV Medicine, 24, pp. 1126–1136. Available at: https://doi.org/10.1111/hiv.13542.

Avery Emma F et al. (2023) ‘Leukocyte Count and Coronary Artery Disease Events in People with Human Immunodeficiency Virus: A Longitudinal Study’, Clinical Infectious Diseases, 76, pp. 1969–1979. Available at: https://doi.org/10.1093/cid/ciad033.

Bettonte S, Berton M and Marzolini C (2023) ‘What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?’, 19(5). Available at: https://doi.org/10.1080/17425255.2023.2223961.

Thoueille, P. et al. (2023) ‘Real-World Trough Concentrations and Effectiveness of Long-Acting Cabotegravir and Rilpivirine: A Multicenter Prospective Observational Study in Switzerland’. Elsevier BV. Available at: https://doi.org/10.2139/ssrn.4584084.

Hamusonde, Kalongo et al. (2023) ‘Triggers of Change in Sexual Behavior Among People With HIV: The Swiss U = U Statement and COVID-19 Compared’, Journal of Infectious Diseases, 227, pp. 407–411. Available at: https://doi.org/10.1093/infdis/jiac459.

Hofmann, Eveline et al. (2023) ‘Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection’, Clinical Infectious Diseases, 76, pp. 730–733. Available at: https://doi.org/10.1093/cid/ciac823.

Labarile, Marco et al. (2023) ‘Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach’, Journal of Infectious Diseases, 227, pp. 554–564. Available at: https://doi.org/10.1093/infdis/jiac457.

Otte, Fabian et al. (2023) ‘Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods’, Cell Reports Methods, 3. Available at: https://doi.org/10.1016/j.crmeth.2023.100485.

Paioni P. et al. (2023) ‘Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study’, The Lancet Regional Health - Europe, 31. Available at: https://doi.org/10.1016/j.lanepe.2023.100656.

Schoepf, Isabella C et al. (2023) ‘Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years’, The Lancet Healthy Longevity, 4, pp. e211–e218. Available at: https://doi.org/10.1016/s2666-7568(23)00037-5.

Schwenke, Johannes M et al. (2023) ‘Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study’, Journal of Infectious Diseases, 228, pp. 742–750. Available at: https://doi.org/10.1093/infdis/jiad179.

Thoueille, Paul et al. (2023) ‘Population pharmacokinetic analysis of doravirine in real-world people with HIV’, British Journal of Clinical Pharmacology, null. Available at: https://doi.org/10.1111/bcp.15975.

Marzolini C et al. (2022) ‘Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.’, Clinical pharmacology and therapeutics, 112(6), pp. 1191–1200. Available at: https://doi.org/10.1002/cpt.2646.

Aebi-Popp K et al. (2022) ‘Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.’, The Journal of antimicrobial chemotherapy, 77(12), pp. 3436–3442. Available at: https://doi.org/10.1093/jac/dkac337.

Catho G et al. (2022) ‘Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals.’, The Lancet. Infectious diseases, 22(10), pp. 1493–1502. Available at: https://doi.org/10.1016/s1473-3099(22)00308-5.

Franchini F et al. (2022) ‘Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics-Why Time Is Essential for Meaningful Collaborations.’, JMIR formative research, 6(9), p. e36759. Available at: https://doi.org/10.2196/36759.

Berton M et al. (2022) ‘Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.’, Clinical pharmacokinetics, 61(9), pp. 1251–1270. Available at: https://doi.org/10.1007/s40262-022-01132-3.

Ryom L et al. (2022) ‘Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.’, HIV medicine, 23(8), pp. 849–858. Available at: https://doi.org/10.1111/hiv.13268.

Girardin F et al. (2022) ‘Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.’, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 28(8), pp. 1044–1046. Available at: https://doi.org/10.1016/j.cmi.2022.03.030.

Thoueille P et al. (2022) ‘Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.’, Pharmaceutics, 14(8). Available at: https://doi.org/10.3390/pharmaceutics14081588.

Otten LS et al. (2022) ‘Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.’, European respiratory review : an official journal of the European Respiratory Society, 31(164). Available at: https://doi.org/10.1183/16000617.0004-2022.

Stader F and Marzolini C (2022) ‘Sex-related pharmacokinetic differences with aging.’, European geriatric medicine, 13(3), pp. 559–565. Available at: https://doi.org/10.1007/s41999-021-00587-0.

Marzolini C et al. (2022) ‘Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.’, 175(5). Available at: https://doi.org/10.7326/m22-0281.

Zino L et al. (2022) ‘Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.’, Clinical pharmacokinetics, 61(5), pp. 619–635. Available at: https://doi.org/10.1007/s40262-022-01120-7.

Bettonte S, Berton M and Marzolini C (2022) ‘Magnitude of Drug-Drug Interactions in Special Populations.’, Pharmaceutics, 14(4). Available at: https://doi.org/10.3390/pharmaceutics14040789.

Marzolini C et al. (2022) ‘Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.’, Clinical pharmacokinetics, 61(3), pp. 339–346. Available at: https://doi.org/10.1007/s40262-021-01098-8.

Marzolini C et al. (2022) ‘Fluvoxamine for the treatment of COVID-19.’, 10(3). Available at: https://doi.org/10.1016/s2214-109x(21)00592-1.

Stader F et al. (2022) ‘Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.’, Clinical pharmacology and therapeutics, 111(3), pp. 579–584. Available at: https://doi.org/10.1002/cpt.2402.

Jacobs TG et al. (2022) ‘Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.’, The Journal of antimicrobial chemotherapy, 77(3), pp. 568–573. Available at: https://doi.org/10.1093/jac/dkab412.

Scherrer AU et al. (2022) ‘Cohort Profile Update: The Swiss HIV Cohort Study (SHCS).’, International journal of epidemiology, 51(1), pp. 33–34j. Available at: https://doi.org/10.1093/ije/dyab141.

Chiesa A.F. et al. (2022) ‘Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study’, Antiviral Therapy, 27(1). Available at: https://doi.org/10.1177/13596535211068613.

Jakeman B et al. (2022) ‘Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.’, The Journal of antimicrobial chemotherapy, 77(2), pp. 492–499. Available at: https://doi.org/10.1093/jac/dkab386.

Duran Ramirez JJ et al. (2022) ‘Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study’, Journal of Infectious Diseases, 225(2), pp. 306–316. Available at: https://doi.org/10.1093/infdis/jiab360.

Balakrishna, Suraj et al. (2022) ‘Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study’, Journal of Infectious Diseases, 225, pp. 1592–1600. Available at: https://doi.org/10.1093/infdis/jiab573.

Bick, Alexander G. et al. (2022) ‘Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV (Scientific Reports, (2022), 12, 1, (577), 10.1038/s41598-021-04308-2)’, Scientific Reports, 12. Available at: https://doi.org/10.1038/s41598-022-16151-0.

Bick, Alexander G. et al. (2022) ‘Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV’, Scientific Reports, 12. Available at: https://doi.org/10.1038/s41598-021-04308-2.

Chaudron, S. E. et al. (2022) ‘A systematic molecular epidemiology screen reveals numerous human immunodeficiency virus (HIV) type 1 superinfections in the Swiss HIV Cohort Study’, J Infect Dis, 226(7), pp. 1256–1266. Available at: https://doi.org/10.1093/infdis/jiac166.

Hachfeld A. et al. (2022) ‘Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)’, HIV Medicine, 23, pp. 417–425. Available at: https://doi.org/10.1111/hiv.13255.

Jakeman, Bernadette et al. (2022) ‘Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus’, Open Forum Infectious Diseases, 9. Available at: https://doi.org/10.1093/ofid/ofac457.

Schoepf, Isabella C. et al. (2022) ‘Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years’, Journal of Infectious Diseases, 225, pp. 1581–1591. Available at: https://doi.org/10.1093/infdis/jiab603.

Gussago S et al. (2021) ‘Simultaneous Propionibacterium avidum and Propionibacterium acnes Chronic Periprosthetic Hip Joint Infection: A Case Report.’, 13(12). Available at: https://doi.org/10.7759/cureus.20771.

Schoepf IC et al. (2021) ‘Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study.’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(9), pp. 1597–1604. Available at: https://doi.org/10.1093/cid/ciab521.

Stader F, Battegay M and Marzolini C (2021) ‘Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.’, Clinical pharmacology and therapeutics, 110(5), pp. 1231–1239. Available at: https://doi.org/10.1002/cpt.2221.

Allavena C and Marzolini C (2021) ‘Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions?’, 2(10). Available at: https://doi.org/10.1016/s2666-7568(21)00227-0.

Pyngottu A. et al. (2021) ‘Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment’, Clinical Infectious Diseases, 73(7), pp. E2134–E2141. Available at: https://doi.org/10.1093/cid/ciaa1614.

Hollinger A et al. (2021) ‘Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.’, AIDS research and therapy, 18(1), p. 56. Available at: https://doi.org/10.1186/s12981-021-00382-8.

Treglia G et al. (2021) ‘Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[(18)F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis.’, Pharmaceuticals (Basel, Switzerland), 14(8). Available at: https://doi.org/10.3390/ph14080762.

Courlet P et al. (2021) ‘Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.’, European journal of clinical pharmacology, 77(7), pp. 979–987. Available at: https://doi.org/10.1007/s00228-020-03060-2.

Hodge D et al. (2021) ‘Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.’, Clinical pharmacokinetics, 60(7), pp. 835–853. Available at: https://doi.org/10.1007/s40262-021-01005-1.

Stoira E, Chiesa AF and Elzi L (2021) ‘“High prevalence of heterotopic ossification in critically ill patients with severe COVID-19” - Author’s reply.’, 27(7). Available at: https://doi.org/10.1016/j.cmi.2021.02.004.

Stoira E et al. (2021) ‘High prevalence of heterotopic ossification in critically ill patients with severe COVID-19.’, 27(7). Available at: https://doi.org/10.1016/j.cmi.2020.12.037.

Istampoulouoglou I et al. (2021) ‘Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre.’, Global cardiology science & practice, 2021(2), p. e202111. Available at: https://doi.org/10.21542/gcsp.2021.11.

Chammartin F et al. (2021) ‘Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study’, Annals of Internal Medicine, 174(6), pp. 768–776. Available at: https://doi.org/10.7326/m20-5226.

Reichmuth M.L. et al. (2021) ‘Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission’, HIV Medicine, 22(5), pp. 346–359. Available at: https://doi.org/10.1111/hiv.13030.

Bentzon, A.K. et al. (2021) ‘Healthcare delivery for HIV-positive people with tuberculosis in Europe’, HIV Medicine, 22(4), pp. 283–293. Available at: https://doi.org/10.1111/hiv.13016.

Stader F et al. (2021) ‘Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.’, Clinical pharmacology and therapeutics, 109(4), pp. 1025–1029. Available at: https://doi.org/10.1002/cpt.2178.

Courlet P et al. (2021) ‘Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.’, Clinical pharmacokinetics, 60(3), pp. 379–390. Available at: https://doi.org/10.1007/s40262-020-00946-3.

Darling KEA et al. (2021) ‘Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland’, PLoS ONE, 16(3 March). Available at: https://doi.org/10.1371/journal.pone.0246579.

Marra F et al. (2021) ‘Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.’, Drugs in R&D, 21(1), pp. 9–27. Available at: https://doi.org/10.1007/s40268-020-00333-0.

Marzolini C et al. (2021) ‘Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.’, 44(2). Available at: https://doi.org/10.1007/s40264-020-01025-z.

Piccoli L et al. (2021) ‘Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland.’, The Lancet regional health. Europe, 1, p. 100013. Available at: https://doi.org/10.1016/j.lanepe.2020.100013.

Back, David et al. (2021) ‘COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions’, British Journal of Clinical Pharmacology, 87(1), pp. 212–213. Available at: https://doi.org/10.1111/bcp.14358.

Balakrishna, Suraj et al. (2021) ‘Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study’, PLoS Computational Biology, 17. Available at: https://doi.org/10.1371/journal.pcbi.1009529.

Castillo-Mancilla, J. R. et al. (2021) ‘Association of incomplete adherence to antiretroviral therapy with cardiovascular events and mortality in virologically suppressed persons with HIV: the Swiss HIV cohort study’, Open Forum Infect Dis, 8(2), p. ofab032. Available at: https://doi.org/10.1093/ofid/ofab032.

Deutschmann, Elisabeth et al. (2021) ‘Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors’, Clinical Infectious Diseases, 73(7), pp. e2145–e2152. Available at: https://doi.org/10.1093/cid/ciaa918.

Dietrich, Léna G et al. (2021) ‘Rapid Progression of Kidney Dysfunction in People Living with HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores’, Journal of Infectious Diseases, 223, pp. 2145–2153. Available at: https://doi.org/10.1093/infdis/jiaa695.

Hovaguimian, Frédérique et al. (2021) ‘Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis’, Nature Communications, 12. Available at: https://doi.org/10.1038/s41467-021-21485-w.

Kovari H. et al. (2021) ‘Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study’, HIV Medicine, 22, pp. 623–628. Available at: https://doi.org/10.1111/hiv.13106.

Kümmerle, A. et al. (2021) ‘Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study’, J Antimicrob Chemother, 76(10), pp. 2681–2689. Available at: https://doi.org/10.1093/jac/dkab254.

Mari, Alfredo et al. (2021) ‘Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance’, Microorganisms, 9(5), p. 1094. Available at: https://doi.org/10.3390/microorganisms9051094.